All IXCHIQ® articles
-
NewsValneva provides update on recommendations for use of IXCHIQ® in UK
Valneva SE has announced that following a review of the benefits and risks of the Company’s single-dose chikungunya vaccine, IXCHIQ® , the United Kingdom’s (UK) Commission on Human Medicines (CHM) has updated its recommendations for use of the vaccine.
-
NewsValneva provides update on Chikungunya vaccine IXCHIQ®
Valneva SE has announced that the company has decided to voluntarily withdraw the biologics license application (BLA) and Investigational New Drug (IND) application for its chikungunya vaccine, IXCHIQ® , in the United States, following suspension of the license by the FDA.
-
NewsValneva reports high sustained immune response in adolescents one year after Chikungunya Vaccine
Valneva SE, a specialty vaccine company, has reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination.
-
NewsValneva vaccinates first participant in pediatric trial of single-shot Chikungunya vaccine
Valneva SE has announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.